A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging with Hepatocyte-Specific Contrast Agents: Uses,Findings,and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine
Restricted accessResearch articleFirst published online August, 2017
A Pictorial Review of Hepatobiliary Magnetic Resonance Imaging with Hepatocyte-Specific Contrast Agents: Uses,Findings,and Pitfalls of Gadoxetate Disodium and Gadobenate Dimeglumine
Magnetic resonance imaging (MRI) has a well-established role as a highly specific and accurate modality for characterizing benign and malignant focal liver lesions. In particular, contrast-enhanced MRI using hepatocyte-specific contrast agents (HSCAs) improves lesion detection and characterization compared to other imaging modalities and MRI techniques. In this pictorial review, the mechanism of action of gadolinium-based MRI contrast agents, with a focus on HSCAs, is described. The clinical indications, protocols, and emerging uses of the 2 commercially available combined contrast agents available in the United States, gadoxetate disodium and gadobenate dimeglumine, are discussed. The MRI features of these agents are compared with examples of focal hepatic masses, many of which have been obtained within the same patient therefore allowing direct lesion comparison. Finally, the pitfalls in the use of combined contrast agents in liver MRI are highlighted.
SealeM.K.CatalanoO.A.SainiS.HahnP.F.SahaniD.V.Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary treeRadiographics2009; 29:1725–1748.
2.
GoodwinM.D.DobsonJ.E.SirlinC.B.LimB.G.StellaD.L.Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agentsRadiographics2011; 31:1547–1568.
3.
RingeK.I.HusarikD.B.SirlinC.B.MerkleE.M.Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liverAJR Am J Roentgenol2010; 195:13–28.
4.
JhaveriK.ClearyS.AudetP.Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid)AJR Am J Roentgenol2015; 204:498–509.
5.
DavenportM.S.VigliantiB.L.Al-HawaryM.M.Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image qualityRadiology2013; 266:452–461.
6.
van KesselC.S.VeldhuisW.B.van den BoschM.A.A.J.van LeeuwenM.S.MR liver imaging with Gd-EOB-DTPA: a delay time of 10 minutes is sufficient for lesion characterisationEur Radiol2012; 22:2153–2160.
7.
TamadaT.ItoK.HigakiA.Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic liversEur J Radiol2011; 80:e311–e316.
8.
KimH.Y.ChoiJ.Y.ParkC.-H.Clinical factors predictive of insufficient liver enhancement on the hepatocyte-phase of Gd-EOB-DTPA-enhanced magnetic resonance imaging in patients with liver cirrhosisJ Gastroenterol2013; 48:1180–1187.
9.
GschwendS.EbertW.Schultze-MosgauM.BreuerJ.Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairmentInvest Radiol2011; 46:556–566.
10.
CruiteI.SchroederM.MerkleE.M.SirlinC.B.Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liverAJR Am J Roentgenol2010; 195:29–41.
11.
MotosugiU.IchikawaT.SanoK.Double-dose gadoxetic Acid-enhanced magnetic resonance imaging in patients with chronic liver diseaseInvest Radiol2011; 46:141–145.
12.
GrazioliL.MoranaG.KirchinM.A.SchneiderG.Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective studyRadiology2005; 236:166–177.
13.
ChangS.D.StunellH.A pictorial review of the MRI appearances of focal liver lesionsJ Med Imaging Radiat Sci2010; 41:180–195.
14.
ReddyK.R.KligermanS.LeviJ.Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcomeAm Surg2001; 67:173–178.
15.
HuppertzA.HaraidaS.KrausA.Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT–initial observationsRadiology2005; 234:468–478.
16.
BurkeC.Alexander GrantL.GohV.GriffinN.The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imagingSemin Ultrasound CT MR2013; 34:44–53.
17.
Bioulac-SageP.RebouissouS.Sa CunhaA.Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liverGastroenterology2005; 128:1211–1218.
18.
AgarwalS.Fuentes-OrregoJ.M.ArnasonT.Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRIAJR Am J Roentgenol2014; 203:W408–W414.
19.
KhannaM.RamanathanS.FasihN.SchiedaN.VirmaniV.McInnesM.D.F.Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenomaInsights Imaging2015; 6:347–362.
20.
van AaltenS.M.ThomeerM.G.J.TerkivatanT.Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classificationRadiology2011; 261:172–181.
21.
DooK.W.LeeC.H.ChoiJ.W.LeeJ.KimK.A.ParkC.M.“Pseudo washout” sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumorAJR Am J Roentgenol2009; 193:W490–W496.
22.
FuG.-L.DuY.ZeeC.-S.Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesionsJ Comput Assist Tomogr2012; 36:14–19.
23.
HaS.LeeC.H.KimB.H.Paradoxical uptake of Gd-EOB-DTPA on the hepatobiliary phase in the evaluation of hepatic metastasis from breast cancer: is the “target sign” a common finding?Magn Reson Imaging2012; 30:1083–1090.
24.
HammerstinglR.HuppertzA.BreuerJ.Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesionsEur Radiol2008; 18:457–467.
25.
ChoiJ.-Y.ChoiJ.-S.KimM.-J.Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agentJ Magn Reson Imaging2010; 31:571–578.
26.
ZechC.J.HerrmannK.A.ReiserM.F.SchoenbergS.O.MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPAMagn Reson Med Sci2007; 6:43–52.
27.
ChenL.ZhangJ.ZhangL.Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastasesPloS One72012e48681
28.
van KesselC.S.BuckensC.F.M.van den BoschM.A.A.J.van LeeuwenM.S.van HillegersbergR.VerkooijenH.M.Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysisAnn Surg Oncol2012; 19:2805–2813.
29.
Berger-KulemannV.SchimaW.BaroudS.Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of referenceEur J Surg Oncol2012; 38:670–676.
30.
NaritaM.HatanoE.ArizonoS.Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinomaJ Gastroenterol2009; 44:793–798.
31.
LeeS.A.LeeC.H.JungW.Y.Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experienceMagn Reson Imaging2011; 29:83–90.
32.
KitaoA.ZenY.MatsuiO.Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging–correlation with molecular transporters and histopathologic featuresRadiology2010; 256:817–826.
33.
SaitoK.KotakeF.ItoN.Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phaseMagn Reson Med Sci2005; 4:1–9.
34.
SanoK.IchikawaT.MotosugiU.Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imagingRadiology2011; 261:834–844.
35.
BashirM.R.GuptaR.T.DavenportM.S.Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?J Magn Reson Imaging2013; 37:398–406.
36.
BaekC.-K.ChoiJ.-Y.KimK.-A.Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCTClin Radiol2012; 67:148–156.
37.
KimT.K.LeeK.H.JangH.-J.Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinomaRadiology2011; 259:730–738.
38.
SunH.Y.LeeJ.M.ParkH.S.Gadoxetic acid-enhanced MRI with MR cholangiography for the preoperative evaluation of bile duct cancerJ Magn Reson Imaging2013; 38:138–147.
39.
PaolantonioP.LaghiA.VanzulliA.MRI of hepatic epithelioid hemangioendothelioma (HEH)J Magn Reson Imaging2014; 40:552–558.
40.
KimE.H.RhaS.E.LeeY.J.YooI.R.JungE.S.ByunJ.Y.CT and MR imaging findings of hepatic epithelioid hemangioendotheliomas: emphasis on single nodular typeAbdom Imaging2015; 40:500–509.
41.
WillattJ.M.HussainH.K.AdusumilliS.MarreroJ.A.MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversiesRadiology2008; 247:311–330.
42.
HannaR.F.AguirreD.A.KasedN.EmeryS.C.PetersonM.R.SirlinC.B.Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging featuresRadiographics2008; 28:747–769.
43.
RheeH.KimM.-J.ParkM.-S.KimK.A.Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRIBr J Radiol2012; 85:e837–e844.
44.
MoranaG.GrazioliL.KirchinM.A.Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administrationInvest Radiol2011; 46:225–239.
45.
ChouC.-T.ChenY.-L.SuW.-W.WuH.-K.ChenR.-C.Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocyte-phase imagingJ Magn Reson Imaging2010; 32:895–902.
